European Heart Journal Advance Access originally published online on June 3, 2008
European Heart Journal 2008 29(15):1807-1818; doi:10.1093/eurheartj/ehn220
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Autologous bone marrow stem cells to treat acute myocardial infarction: a systematic review
1 Stem Cell Research Laboratory, NHS-Blood and Transplant, John Radcliffe Hospital, Headington, Oxford OX3 9BQ, UK
2 Nuffield Department of Clinical Laboratory Sciences, University of Oxford, Oxford, UK
3 Systematic Reviews Initiative, Clinical Research Group, NHSBT-Oxford, John Radcliffe Hospital, Oxford, UK
4 Department of Clinical Pharmacology, William Harvey Research Institute, Charterhouse Square, London, UK
Received 19 December 2007; revised 23 April 2008; accepted 6 May 2008; online publish-ahead-of-print 3 June 2008.
* Corresponding author. Tel: +44 1865 447 934, Fax: +44 1865 447 931, Email: enca.martin-rendon{at}nbs.nhs.uk;enca.rendon{at}ndcsl.ox.ac.uk
Aims: To provide systematic assessment of the safety and efficacy of autologous bone marrow-derived stem cell (BMSC) transplantation in acute myocardial infarction (AMI) based on clinical evidence.
Methods and results: The search strategy included MEDLINE, EMBASE, the Cochrane Library, and Current Controlled Trials Register through to August 2007 for randomized controlled trials of BMSC treatment for AMI. Thirteen trials (14 comparisons) with a total of 811 participants were included. Data were analysed using a random effects model. Overall, stem cell therapy improved left ventricular ejection fraction (LVEF) by 2.99% [95% confidence interval (CI), 1.26–4.72%, P = 0.0007], significantly reduced left ventricular end-systolic volume (LVESV) by 4.74 mL (95% CI, –7.84 to –1.64 mL, P = 0.003), and myocardial lesion area by 3.51% (95% CI, –5.91 to –1.11%, P = 0.004) compared with controls. Subgroup analysis revealed that there was statistical significant difference in LEVF in favour of BMSCs when cells were infused within 7 days following AMI and when the BMSC dose administered was higher than 108 BMSCs. In addition, there were trends in favour of benefit for most clinical outcomes examined, although it should be acknowledged that the 95%CI included no significant difference.
Conclusion: Stem cell treatment for AMI still holds promise. Clinically, these data suggest that improvement over conventional therapy can be achieved. Further, adequately powered trials using optimal dosing, longer term outcome assessments, more reliable, and more patient-centred outcomes are required.
Key Words: Stem cells • Myocardial infarction • Bone marrow • Systematic review • Randomized clinical trials
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  A. Gianella, U. Guerrini, M. Tilenni, L. Sironi, G. Milano, E. Nobili, S. Vaga, M. C. Capogrossi, E. Tremoli, and M. Pesce Magnetic resonance imaging of human endothelial progenitors reveals opposite effects on vascular and muscle regeneration into ischaemic tissues Cardiovasc Res, October 31, 2009; (2009) cvp325v2. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. S. Feigenbaum, L. Lemberg, and J. M. Hare Tracking cell fate with noninvasive imaging. J. Am. Coll. Cardiol., October 20, 2009; 54(17): 1627 - 1628. [Full Text] [PDF]
|
|
|
|
 |
|
 V. K. Lai, K.-L. Ang, W. Rathbone, N. J. Harvey, and M. Galinanes Randomized controlled trial on the cardioprotective effect of bone marrow cells in patients undergoing coronary bypass graft surgery Eur. Heart J., October 1, 2009; 30(19): 2354 - 2359. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. O'Brien and F. P. Barry Stem Cell Therapy and Regenerative Medicine Mayo Clin. Proc., October 1, 2009; 84(10): 859 - 861. [Full Text] [PDF]
|
|
|
|
|
|
B. J. Gersh, R. D. Simari, A. Behfar, C. M. Terzic, and A. Terzic Cardiac Cell Repair Therapy: A Clinical Perspective Mayo Clin. Proc., October 1, 2009; 84(10): 876 - 892. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. J. Brunskill, C. J. Hyde, C. J. Doree, S. M. Watt, and E. Martin-Rendon Route of delivery and baseline left ventricular ejection fraction, key factors of bone-marrow-derived cell therapy for ischaemic heart disease Eur J Heart Fail, September 1, 2009; 11(9): 887 - 896. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Cao, D. Sun, C. Li, K. Narsinh, L. Zhao, X. Li, X. Feng, J. Zhang, Y. Duan, J. Wang, et al. Long-term myocardial functional improvement after autologous bone marrow mononuclear cells transplantation in patients with ST-segment elevation myocardial infarction: 4 years follow-up Eur. Heart J., August 2, 2009; 30(16): 1986 - 1994. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. R. Dixon, C. L. Grines, and W. W. O'Neill The year in interventional cardiology. J. Am. Coll. Cardiol., June 2, 2009; 53(22): 2080 - 2097. [Full Text] [PDF]
|
|
|
|
 |
|
 C. Stamm, Y.-H. Choi, B. Nasseri, and R. Hetzer A heart full of stem cells: the spectrum of myocardial progenitor cells in the postnatal heart Therapeutic Advances in Cardiovascular Disease, June 1, 2009; 3(3): 215 - 229. [Abstract] [PDF]
|
|
|
|
|
|
M. Tendera, W. Wojakowski, W. Ruzyllo, L. Chojnowska, C. Kepka, W. Tracz, P. Musialek, W. Piwowarska, J. Nessler, P. Buszman, et al. Intracoronary infusion of bone marrow-derived selected CD34+CXCR4+ cells and non-selected mononuclear cells in patients with acute STEMI and reduced left ventricular ejection fraction: results of randomized, multicentre Myocardial Regeneration by Intracoronary Infusion of Selected Population of Stem Cells in Acute Myocardial Infarction (REGENT) Trial Eur. Heart J., June 1, 2009; 30(11): 1313 - 1321. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
U. Landmesser Bone marrow cell therapy after myocardial infarction. What should we select? Eur. Heart J., June 1, 2009; 30(11): 1310 - 1312. [Full Text] [PDF]
|
|
|
|
 |
|
 P. Menasche Stem Cell Therapy for Heart Failure: Are Arrhythmias a Real Safety Concern? Circulation, May 26, 2009; 119(20): 2735 - 2740. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Mollmann, H. Nef, A. Elsasser, and C. Hamm Stem cells in myocardial infarction: from bench to bedside Heart, March 15, 2009; 95(6): 508 - 514. [Full Text] [PDF]
|
|